Table Info

Table 1.

Various types of nanoparticles with their beneficial attributes and limitations

Types of nanoparticles	Beneficial attributes	Limitations	References
PBCA	Low peripheral toxicity Quick biodegrading synthetic polymer Lower molecular weight	Lack of long circulating as drug carriers	[91, 92]
IONPs	High surface area to volume ratio Apt for biosensing & drug delivery Minimal toxicity Excellent superparamagnetism, biocompatibility Stability in aqueous solution	High permeability Probability of contamination Feeble bonding	[93]
FA combined with PEG	Enhances FA receptor mediated targeting delivery	Insufficient drug release Fast drug release Unstable storage	[94]
PLA nanoparticles	Sustained drug release period, biodegradable & biocompatible	Low cell adhesion biological inertness Low degradation rate Acid degradation by-products	[95]

Declarations

Acknowledgments

The authors acknowledge Jaypee Institute of Information Technology, Noida, for providing the entire infrastructure to complete this project.

Author contributions

M Singh and DJ contributed in conceptualization, design of the work, resourcing, interpretation of data. M Singh, DJ, VA, DP, M Sharma, and PP contributed to writing—original draft, and writing—review & editing; M Singh, SM, and R contributed in supervision; M Singh, DJ, SM and R contributed in data curation, and validation.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Jain KK. A critical overview of targeted therapies for glioblastoma. Front Oncol. 2018;8:419. [DOI] [PubMed] [PMC]

Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma. Brisbane: Codon Publications; 2017. pp. 143–53. [DOI]

Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20:S2–8. [DOI] [PubMed] [PMC]

Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee ShU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18:3–9. [DOI] [PubMed] [PMC]

Zong H, Parada LF, Baker SJ. Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harb Perspect Biol. 2015;7:a020610. [DOI] [PubMed] [PMC]

Grochans S, Cybulska AM, Simińska D, Korbecki J, Kojder K, Chlubek D, et al. Epidemiology of glioblastoma multiforme-literature review. Cancers. 2022;14:2412. [DOI] [PubMed] [PMC]

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–12. [DOI] [PubMed] [PMC]

Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell. 2012;149:36–47. [DOI] [PubMed] [PMC]

Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther. 2015;152:63–82. [DOI] [PubMed]

10.

Wilson TA, Karajannis MA, Harter DH. Glioblastoma multiforme: state of the art and future therapeutics. Surg Neurol Int. 2014;5:64. [DOI] [PubMed] [PMC]

11.

Young RM, Jamshidi A, Davis G, Sherman JH. Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med. 2015;3:121. [DOI] [PubMed] [PMC]

12.

Vitucci M, Hayes DN, Miller CR. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer. 2011;104:545–53. [DOI] [PubMed] [PMC]

13.

Ghosh D, Nandi S, Bhattacharjee S. Combination therapy to checkmate glioblastoma: clinical challenges and advances. Clin Transl Med. 2018;7:33. [DOI] [PubMed] [PMC]

14.

Fernandes C, Costa A, Osório L, Lago RC, Linhares P, Carvalho B, et al. Current standards of care in glioblastoma therapy. In: De Vleeschouwer S, editor. Glioblastoma. Brisbane: Codon Publications; 2017. pp. 197–241. [DOI] [PubMed]

15.

Rajagopalan S, Huang F, Fersht AR. Single-molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53. Nucleic Acids Res. 2011;39:2294–303. [DOI] [PubMed] [PMC]

16.

Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 1995;267:1498–502. [DOI] [PubMed]

17.

Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell. 2006;124:207–19. [DOI] [PubMed]

18.

Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13:83–96. [DOI] [PubMed] [PMC]

19.

Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170:1062–78. [DOI] [PubMed] [PMC]

20.

Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2:466–74. [DOI] [PubMed] [PMC]

21.

Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, et al. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene. 2000;19:3816–22. [DOI] [PubMed]

22.

Ghimenti C, Fiano V, Chiadò-Piat L, Chiò A, Cavalla P, Schiffer D. Deregulation of the p14ARF/Mdm2/p53 pathway and G₁/S transition in two glioblastoma sets. J Neurooncol. 2003;61:95–102. [DOI] [PubMed]

23.

Rickert CH, Riemenschneider MJ, Schachenmayr W, Richter HP, Bockhorn J, Reifenberger G, et al. Glioblastoma with adipocyte-like tumor cell differentiation—histological and molecular features of a rare differentiation pattern. Brain Pathol. 2009;19:431–8. [DOI] [PubMed] [PMC]

24.

Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G, et al. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 2013;41:D962–9. [DOI] [PubMed] [PMC]

25.

Zadeh MD, Amini R, Firoozray M, Derakhshandeh-Peykar P. Frequent homozygous deletion of p16/CDKN2A gene in malignant gliomas of Iranian patients. Pak J Biol Sci. 2007;10:4246–50. [DOI] [PubMed]

26.

Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, et al. RB-dependent S-phase response to DNA damage. Mol Cell Biol. 2000;20:7751–63. [DOI] [PubMed] [PMC]

27.

Biasoli D, Kahn SA, Cornélio TA, Furtado M, Campanati L, Chneiweiss H, et al. Retinoblastoma protein regulates the crosstalk between autophagy and apoptosis, and favors glioblastoma resistance to etoposide. Cell Death Dis. 2013;4:e767. [DOI] [PubMed] [PMC]

28.

Nakada M, Kita D, Watanabe T, Hayashi Y, Teng L, Pyko IV, et al. Aberrant signaling pathways in glioma. Cancers. 2011;3:3242–78. [DOI] [PubMed] [PMC]

29.

Regad T. Targeting RTK signaling pathways in cancer. Cancers. 2015;7:1758–84. [DOI] [PubMed] [PMC]

30.

Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268–72. [DOI] [PubMed]

31.

Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003;12:541–52. [DOI] [PubMed]

32.

Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1997;1332:F105–26. [DOI] [PubMed]

33.

The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–8. Erratum in: Nature. 2013;494:506. [DOI] [PubMed] [PMC]

34.

Montano N, Cenci T, Martini M, D’Alessandris QG, Pelacchi F, Ricci-Vitiani L, et al. Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia. 2011;13:1113–21. [DOI] [PubMed] [PMC]

35.

Heimberger AB, Suki D, Yang D, Shi W, Aldape K. The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med. 2005;3:38. [DOI] [PubMed] [PMC]

36.

McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000;5 Suppl 1:3–10. [DOI] [PubMed]

37.

Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 2002;62:3729–35. [PubMed]

38.

Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2014;142:164–75. [DOI] [PubMed]

39.

Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene. 2008;27:5527–41. [DOI] [PubMed]

40.

Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A. 2000;97:11960–5. [DOI] [PubMed] [PMC]

41.

Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 2013;71:829–42. [DOI] [PubMed]

42.

Vuong HG, Altibi AMA, Duong UNP, Ngo HTT, Pham TQ, Fung KM, et al. BRAF mutation is associated with an improved survival in glioma—a systematic review and meta-analysis. Mol Neurobiol. 2018;55:3718–24. [DOI] [PubMed]

43.

Gadji M, Crous AMT, Fortin D, Krcek J, Torchia M, Mai S, et al. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts. Eur J Pharmacol. 2009;625:23–30. [DOI] [PubMed]

44.

Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009;16:748–54. [DOI] [PubMed]

45.

Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14^ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999;9:469–79. [DOI] [PubMed] [PMC]

46.

Schiebe M, Ohneseit P, Hoffmann W, Meyermann R, Rodemann HP, Bamberg M. Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol. 2000;49:197–203. [DOI] [PubMed]

47.

Yu W, Zhang L, Wei Q, Shao A. O⁶-methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy. Front Oncol. 2020;9:1547. [DOI] [PubMed] [PMC]

48.

Li G, Li Y, Liu X, Wang Z, Zhang C, Wu F, et al. ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. Cell Death Dis. 2018;9:1190. [DOI] [PubMed] [PMC]

49.

Cheng Q, Tang A, Wang Z, Fang N, Zhang Z, Zhang L, et al. CALD1 modulates gliomas progression via facilitating tumor angiogenesis. Cancers. 2021;13:2705. [DOI] [PubMed] [PMC]

50.

Navis AC, van den Eijnden M, Schepens JT, Hooft van Huijsduijnen R, Wesseling P, Hendriks WJ. Protein tyrosine phosphatases in glioma biology. Acta Neuropathol. 2010;119:157–75. [DOI] [PubMed] [PMC]

51.

Albakova Z, Armeev GA, Kanevskiy LM, Kovalenko EI, Sapozhnikov AM. HSP70 multi-functionality in cancer. Cells. 2020;9:587. [DOI] [PubMed] [PMC]

52.

Horská A, Barker PB. Imaging of brain tumors: MR spectroscopy and metabolic imaging. Neuroimaging Clin N Am. 2010;20:293–310. [DOI] [PubMed] [PMC]

53.

Nakamura H, Doi M, Suzuki T, Yoshida Y, Hoshikawa M, Uchida M, et al. The significance of lactate and lipid peaks for predicting primary neuroepithelial tumor grade with proton MR spectroscopy. Magn Reson Med Sci. 2018;17:238–43. [DOI] [PubMed] [PMC]

54.

Chen M, Medarova Z, Moore A. Role of microRNAs in glioblastoma. Oncotarget. 2021;12:1707–23. [DOI] [PubMed] [PMC]

55.

Li J, Xu H, Wang Q, Wang S, Xiong N. 14-3-3ζ promotes gliomas cells invasion by regulating Snail through the PI3K/AKT signaling. Cancer Med. 2019;8:783–94. [DOI] [PubMed] [PMC]

56.

Li G, Shen J, Cao J, Zhou G, Lei T, Sun Y, et al. Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461. J Exp Clin Cancer Res. 2018;37:78. [DOI] [PubMed] [PMC]

57.

Huang J, Yu J, Tu L, Huang N, Li H, Luo Y. Isocitrate dehydrogenase mutations in glioma: from basic discovery to therapeutics development. Front Oncol. 2019;9:506. [DOI] [PubMed] [PMC]

58.

Barajas RF Jr, Chang JS, Segal MR, Parsa AT, McDermott MW, Berger MS, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2009;253:486–96. [DOI] [PubMed] [PMC]

59.

Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol. 2009;30:552–8. [DOI] [PubMed] [PMC]

60.

Baek HJ, Kim HS, Kim N, Choi YJ, Kim YJ. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. Radiology. 2012;264:834–43. [DOI] [PubMed]

61.

Gupta A, Young RJ, Shah AD, Schweitzer AD, Graber JJ, Shi W, et al. Pretreatment dynamic susceptibility contrast MRI perfusion in glioblastoma: prediction of EGFR gene amplification. Clin Neuroradiol. 2015;25:143–50. [DOI] [PubMed] [PMC]

62.

Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, et al. Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol. 2013;34:533–40. [DOI] [PubMed] [PMC]

63.

Korfiatis P, Kline TL, Coufalova L, Lachance DH, Parney IF, Carter RE, et al. MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas. Med Phys. 2016;43:2835–44. [DOI] [PubMed] [PMC]

64.

Larsen VA, Simonsen HJ, Law I, Larsson HB, Hansen AE. Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis. Neuroradiology. 2013;55:361–9. [DOI] [PubMed]

65.

Sasmita AO, Wong YP, Ling APK. Biomarkers and therapeutic advances in glioblastoma multiforme. Asia Pac J Clin Oncol. 2018;14:40–51. [DOI] [PubMed]

66.

Yeini E, Ofek P, Albeck N, Rodriguez Ajamil D, Neufeld L, Eldar-Boock A, et al. Targeting glioblastoma: advances in drug delivery and novel therapeutic approaches. Adv Ther. 2021;4:2000124. [DOI]

67.

Hegde MM, Prabhu S, Mutalik S, Chatterjee A, Goda JS, Rao BSS. Multifunctional lipidic nanocarriers for effective therapy of glioblastoma: recent advances in stimuli-responsive, receptor and subcellular targeted approaches. J Pharm Investig. 2022;52:49–74. [DOI]

68.

Fana M, Gallien J, Srinageshwar B, Dunbar GL, Rossignol J. PAMAM dendrimer nanomolecules utilized as drug delivery systems for potential treatment of glioblastoma: a systematic review. Int J Nanomedicine. 2020;15:2789–808. [DOI] [PubMed] [PMC]

69.

Taiarol L, Formicola B, Magro RD, Sesana S, Re F. An update of nanoparticle-based approaches for glioblastoma multiforme immunotherapy. Nanomedicine. 2020;15:1861–71. [DOI] [PubMed]

70.

Ellis JA, Banu M, Hossain SS, Singh-Moon R, Lavine SD, Bruce JN, et al. Reassessing the role of intra-arterial drug delivery for glioblastoma multiforme treatment. J Drug Deliv. 2015;2015:405735. [DOI] [PubMed] [PMC]

71.

Chehimi M, Boone M, Chivot C, Deramond H, Constans JM, Ly MC, et al. Intra-arterial delivery of idarubicin in two patients with glioblastoma. Case Rep Oncol. 2016;9:499–505. [DOI] [PubMed] [PMC]

72.

Teleanu DM, Chircov C, Grumezescu AM, Volceanov A, Teleanu RI. Blood-brain delivery methods using nanotechnology. Pharmaceutics. 2018;10:269. [DOI] [PubMed] [PMC]

73.

Huang L, Boling W, Zhang JH. Hyperbaric oxygen therapy as adjunctive strategy in treatment of glioblastoma multiforme. Med Gas Res. 2018;8:24–8. [DOI] [PubMed] [PMC]

74.

Wang WJ, Ding JS, Sun Q, Xu X, Chen G. Role of hyperbaric oxygen in glioma: a narrative review. Med Gas Res. 2022;12:1–5. [DOI] [PubMed] [PMC]

75.

Yamamoto T, Tsuboi K, Nakai K, Kumada H, Sakurai H, Matsumura A. Boron neutron capture therapy for brain tumors. Transl Cancer Res. 2013;2:80–6. [DOI]

76.

Mahmoudi K, Bouras A, Bozec D, Ivkov R, Hadjipanayis C. Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy’s history, efficacy and application in humans. Int J Hyperthermia. 2018;34:1316–28. [DOI] [PubMed] [PMC]

77.

Sun J, Guo M, Pang H, Qi J, Zhang J, Ge Y. Treatment of malignant glioma using hyperthermia. Neural Regen Res. 2013;8:2775–82. [DOI] [PubMed] [PMC]

78.

Glas M, Ballo MT, Bomzon Z, Urman N, Levi S, Lavy-Shahaf G, et al. The impact of tumor treating fields on glioblastoma progression patterns. Int J Radiat Oncol Biol Phys. 2022;112:1269–78. [DOI] [PubMed]

79.

Bruinsmann FA, Richter Vaz G, de Cristo Soares Alves A, Aguirre T, Raffin Pohlmann A, Stanisçuaski Guterres S, et al. Nasal drug delivery of anticancer drugs for the treatment of glioblastoma: preclinical and clinical trials. Molecules. 2019;24:4312. [DOI] [PubMed] [PMC]

80.

Wait SD, Prabhu RS, Burri SH, Atkins TG, Asher AL. Polymeric drug delivery for the treatment of glioblastoma. Neuro Oncol. 2015;17 Suppl 2:ii9–23. [DOI] [PubMed] [PMC]

81.

Pulfer SK, Ciccotto SL, Gallo JM. Distribution of small magnetic particles in brain tumor-bearing rats. J Neurooncol. 1999;41:99–105. [DOI] [PubMed]

82.

Alexiou C, Jurgons R, Seliger C, Brunke O, Iro H, Odenbach S. Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting. Anticancer Res. 2007;27:2019–22. [PubMed]

83.

Liang XF, Wang HJ, Luo H, Tian H, Zhang BB, Hao LJ, et al. Characterization of novel multifunctional cationic polymeric liposomes formed from octadecyl quaternized carboxymethyl chitosan/cholesterol and drug encapsulation. Langmuir. 2008;24:7147–53. [DOI] [PubMed]

84.

Zhao M, Li A, Chang J, Fu X, Zhang Z, Yan R, et al. Develop a novel superparamagnetic nano-carrier for drug delivery to brain glioma. Drug Deliv. 2013;20:95–101. [DOI] [PubMed]

85.

Unger EC, Porter T, Culp W, Labell R, Matsunaga T, Zutshi R. Therapeutic applications of lipid-coated microbubbles. Adv Drug Deliv Rev. 2004;56:1291–314. [DOI] [PubMed]

86.

Li J, Zhao J, Tan T, Liu M, Zeng Z, Zeng Y, et al. Nanoparticle drug delivery system for glioma and its efficacy improvement strategies: a comprehensive review. Int J Nanomedicine. 2020;15:2563–82. [DOI] [PubMed] [PMC]

87.

Ebrahimi Shahmabadi H, Movahedi F, Koohi Moftakhari Esfahani M, Alavi SE, Eslamifar A, Mohammadi Anaraki G, et al. Efficacy of cisplatin-loaded polybutyl cyanoacrylate nanoparticles on the glioblastoma. Tumour Biol. 2014;35:4799–806. [DOI] [PubMed]

88.

Norouzi M, Yathindranath V, Thliveris JA, Kopec BM, Siahaan TJ, Miller DW. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles. Sci Rep. 2020;10:11292. [DOI] [PubMed] [PMC]

89.

McCord E, Pawar S, Koneru T, Tatiparti K, Sau S, Iyer AK. Folate receptors’ expression in gliomas may possess potential nanoparticle-based drug delivery opportunities. ACS Omega. 2021;6:4111–8. [DOI] [PubMed] [PMC]

90.

Ramalho MJ, Loureiro JA, Coelho MAN, Pereira MC. Transferrin receptor-targeted nanocarriers: overcoming barriers to treat glioblastoma. Pharmaceutics. 2022;14:279. [DOI] [PubMed] [PMC]

91.

Wilson B. Brain targeting PBCA nanoparticles and the blood-brain barrier. Nanomedicine (Lond). 2009;4:499–502. [DOI] [PubMed]

92.

Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx. 2005;2:108–19. [DOI] [PubMed] [PMC]

93.

Ali A, Zafar H, Zia M, Ul Haq I, Phull AR, Ali JS, et al. Synthesis, characterization, applications, and challenges of iron oxide nanoparticles. Nanotechnol Sci Appl. 2016;9:49–67. [DOI] [PubMed] [PMC]

94.

Narmani A, Rezvani M, Farhood B, Darkhor P, Mohammadnejad J, Amini B, et al. Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems. Drug Dev Res. 2019;80:404–24. [DOI] [PubMed]

95.

Liu S, Qin S, He M, Zhou D, Qin Q, Wang H. Current applications of poly (lactic acid) composites in tissue engineering and drug delivery. Compos B Eng. 2020;199:108238. [DOI]

96.

Hdeib A, Sloan AE. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax^® platform in the treatment of glioblastoma multiforme. CNS Oncol. 2015;4:63–9. [DOI] [PubMed] [PMC]

97.

Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. [DOI] [PubMed] [PMC]

98.

Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies. 2020;9:34. [DOI] [PubMed] [PMC]

99.

Gholamrezanezhad A, Shooli H, Jokar N, Nemati R, Assadi M. Radioimmunotherapy (RIT) in brain tumors. Nucl Med Mol Imaging. 2019;53:374–81. [DOI] [PubMed] [PMC]

100.

Bruton JK, Koeller JM. Recombinant interleukin-2. Pharmacotherapy. 1994;14:635–56. [PubMed]

101.

Zhu S, Liu Y, Wang PC, Gu X, Shan L. Recombinant immunotoxin therapy of glioblastoma: smart design, key findings, and specific challenges. Biomed Res Int. 2017;2017:7929286. [DOI] [PubMed] [PMC]

102.

Oikonomou E, Anastasiou M, Siasos G, Androulakis E, Psyrri A, Toutouzas K, et al. Cancer therapeutics-related cardiovascular complications. Mechanisms, diagnosis and treatment. Curr Pharm Des. 2018;24:4424–35. [DOI] [PubMed]

103.

Kondo S, Ishizaka Y, Okada T, Kondo Y, Hitomi M, Tanaka Y, et al. FADD gene therapy for malignant gliomas in vitro and in vivo. Hum Gene Ther. 1998;9:1599–608. [DOI] [PubMed]

104.

Vernejoul F, Ghénassia L, Souque A, Lulka H, Drocourt D, Cordelier P, et al. Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. Mol Ther. 2006;14:758–67. [DOI] [PubMed]

105.

Zarogoulidis P, Darwiche K, Sakkas A, Yarmus L, Huang H, Li Q, et al. Suicide gene therapy for cancer - current strategies. J Genet Syndr Gene Ther. 2013;4:16849. [DOI] [PubMed] [PMC]

106.

Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia. 2010;12:675–84. [DOI] [PubMed] [PMC]

107.

Kievit FM, Wang K, Ozawa T, Tarudji AW, Silber JR, Holland EC, et al. Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma. Nanomedicine. 2017;13:2131–9. [DOI] [PubMed] [PMC]